Sign In
Buy PFE
$26.04
+0.350 (+1.36%)
At Close: Jun 05, 2026
The Daily Biotech Pulse: Pfizer Goes Shopping, AstraZeneca Inks Bispecific Antibody Deal, Aptinyx Faces Clinical Study Setback, Erytech Jumps On Data And More
12:24pm, Thursday, 07'th Apr 2022 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours:
Stocks In Focus
AstraZeneca In-Licenses Preclinical Bispecific Antibody Candidate From Harbour BioMed For Up To $350M
BA.2 subvariant of omicron accounted for almost 94% of global cases in latest week, the latest sign of how dominant it has become
11:57am, Thursday, 07'th Apr 2022 MarketWatch
The omicron variant of the coronavirus that causes COVID-19 accounted for 99.8% of global new cases in the latest week, the World Health Organization said Wednesday, and the BA.2 subvariant accounted
My Dividend Stock Portfolio: March 2022 Update - 101 Holdings And 29 Buys
05:30am, Thursday, 07'th Apr 2022 Seeking Alpha
The war in Ukraine continues to dominate market movements. Read why I am not selling and predominantly focusing on adding dividend income via select purchases.
Forget Robinhood and Buy These 2 Growth Stocks Instead
03:00pm, Wednesday, 06'th Apr 2022 The Motley Fool
These shares have underperformed the market in the past year, but they could be winners over the long term.
1 Red Flag and 1 Green Flag for Pfizer
12:00pm, Wednesday, 06'th Apr 2022 The Motley Fool
Should we worry about a decline in vaccine revenue?
Pfizer's $6.7 Billion Bet Could Be About to Pay Off Big Time
09:52am, Wednesday, 06'th Apr 2022 The Motley Fool
Positive results for etrasimod could give Pfizer a quick win with its acquisition of Arena.
Why Pfizer Stock Popped on Tuesday
04:20pm, Tuesday, 05'th Apr 2022 The Motley Fool
Citi just laid out a modestly bullish case for Pfizer.
What This Regulatory Approval Could Mean for Merck
03:23pm, Tuesday, 05'th Apr 2022 The Motley Fool
Japan has approved cancer drug Keytruda's pairing with another drug to treat certain kidney cancer patients.
10 Biggest Price Target Changes For Tuesday
12:47pm, Tuesday, 05'th Apr 2022 Benzinga
Piper Sandler cut the price target on The Goldman Sachs Group, Inc. (NYSE: GS) from $465 to $430. Goldman Sachs shares rose 0.1% to $328.60 in pre-market trading.
Wells Fargo boosted Vertex Pharmac
Pfizer (PFE) Stock Sinks As Market Gains: What You Should Know
09:45pm, Monday, 04'th Apr 2022 Zacks Investment Research
Pfizer (PFE) closed the most recent trading day at $50.94, moving -1.22% from the previous trading session.
Will Pfizer (PFE) Beat Estimates Again in Its Next Earnings Report?
04:10pm, Monday, 04'th Apr 2022 Zacks Investment Research
Pfizer (PFE) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Tesla is one of only 11 stocks in the S&P 500, excluding energy, that enjoys this critical support
01:28pm, Saturday, 02'nd Apr 2022 MarketWatch
AMD and Pfizer are among other companies with large increases to EPS estimates.
Moderna's Billion-Dollar mRNA Story Is Just Getting Started
10:00am, Saturday, 02'nd Apr 2022 The Motley Fool
Today's many early-stage programs may deliver tomorrow's products.
U.S. lawmakers close to agreeing on $10 billion in funding for next phase of the COVID-19 battle, as death toll tops 980,000
06:33pm, Friday, 01'st Apr 2022 MarketWatch
U.S. lawmakers moved close to agreeing on a bipartisan compromise to provide a fresh $10 billion to combat COVID-19 on Thursday, a deal that could set up final congressional approval next week.
Novavax (NVAX) Seeks EU Nod for COVID-19 Vaccine in Kids
05:09pm, Friday, 01'st Apr 2022 Zacks Investment Research
Novavax (NVAX) seeks label expansion for its COVID-19 vaccine in adolescents aged 12-17 years in the European Union. Currently, the vaccine is authorized for use in adults.
